Donepezil 5 mg vs placebo
Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 5 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
- Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyOR 0.94 [0.72, 1.22]3 studies · 1772 participantsModerate